Amesika N Nyaku1, Sean G Kelly2, Babafemi O Taiwo3,4. 1. Division of Infectious Diseases, Department of Medicine, Rutgers-New Jersey Medical School, Newark, NJ, USA. 2. Division of Infectious Diseases, Department of Medicine, Vanderbilt University, Nashville, TN, USA. 3. Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine & Center for Global Health, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. b-taiwo@northwestern.edu. 4. Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. b-taiwo@northwestern.edu.
Abstract
PURPOSE OF REVIEW: Current HIV treatment options require daily use of combination antiretroviral drugs. Many persons living with HIV experience treatment fatigue and suboptimal adherence as a result. Long-acting antiretroviral drugs are being developed to expand options for HIV treatment. Here, we review the agents in development, and evaluate data from recent clinical trials. In addition, we anticipate challenges to successful widespread use of long-acting antiretrovirals. RECENT FINDINGS: Parenteral nanosuspensions of cabotegravir and rilpivirine, and dapivirine vaginal ring are the farthest in clinical development. Long-acting modalities in earlier development stages employ drug-loaded implants, microparticles, or targeted mutagenesis, among other innovations. Long-acting antiretroviral drugs promise new options for HIV prevention and treatment, and ways to address poor adherence and treatment fatigue. Further studies will identify the long-acting agents or combinations that are suitable for routine use. Creative solutions will be needed for anticipated implementation challenges.
PURPOSE OF REVIEW: Current HIV treatment options require daily use of combination antiretroviral drugs. Many persons living with HIV experience treatment fatigue and suboptimal adherence as a result. Long-acting antiretroviral drugs are being developed to expand options for HIV treatment. Here, we review the agents in development, and evaluate data from recent clinical trials. In addition, we anticipate challenges to successful widespread use of long-acting antiretrovirals. RECENT FINDINGS: Parenteral nanosuspensions of cabotegravir and rilpivirine, and dapivirine vaginal ring are the farthest in clinical development. Long-acting modalities in earlier development stages employ drug-loaded implants, microparticles, or targeted mutagenesis, among other innovations. Long-acting antiretroviral drugs promise new options for HIV prevention and treatment, and ways to address poor adherence and treatment fatigue. Further studies will identify the long-acting agents or combinations that are suitable for routine use. Creative solutions will be needed for anticipated implementation challenges.
Entities:
Keywords:
HIV prevention; HIV treatment; Long-acting antiretrovirals; Pre-exposure prophylaxis
Authors: Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier Journal: N Engl J Med Date: 2016-02-22 Impact factor: 91.245
Authors: John M Cortez; Rafaela Quintero; John A Moss; Martin Beliveau; Thomas J Smith; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2014-10-13 Impact factor: 5.191
Authors: Aimee Wilkin; Anton L Pozniak; Javier Morales-Ramirez; Sergio H Lupo; Mario Santoscoy; Beatriz Grinsztejn; Kiat Ruxrungtham; Laurence T Rimsky; Simon Vanveggel; Katia Boven Journal: AIDS Res Hum Retroviruses Date: 2011-10-17 Impact factor: 2.205
Authors: Shilpa Viswanathan; Amy C Justice; G Caleb Alexander; Todd T Brown; Neel R Gandhi; Ian R McNicholl; David Rimland; Maria C Rodriguez-Barradas; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: David A Margolis; Cynthia C Brinson; Graham H R Smith; Jerome de Vente; Debbie P Hagins; Joseph J Eron; Sandy K Griffith; Marty H St Clair; Marita C Stevens; Peter E Williams; Susan L Ford; Britt S Stancil; Melinda M Bomar; Krischan J Hudson; Kimberly Y Smith; William R Spreen Journal: Lancet Infect Dis Date: 2015-07-19 Impact factor: 25.071
Authors: Jean B Nachega; Jean-Jacques Parienti; Olalekan A Uthman; Robert Gross; David W Dowdy; Paul E Sax; Joel E Gallant; Michael J Mugavero; Edward J Mills; Thomas P Giordano Journal: Clin Infect Dis Date: 2014-01-22 Impact factor: 9.079
Authors: Kathrine Meyers; Kristina Rodriguez; Robert W Moeller; Ilana Gratch; Martin Markowitz; Perry N Halkitis Journal: PLoS One Date: 2014-12-11 Impact factor: 3.240
Authors: William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai Journal: Drug Deliv Transl Res Date: 2017-12 Impact factor: 4.617
Authors: Christine Tagliaferri Rael; Michelle Martinez; Rebecca Giguere; Walter Bockting; Caitlin MacCrate; Will Mellman; Pablo Valente; George J Greene; Susan G Sherman; Katherine H A Footer; Richard T D'Aquila; Alex Carballo-Diéguez; Thomas J Hope Journal: AIDS Behav Date: 2020-05
Authors: Dipu Karunakaran; Solange M Simpson; Jonathan T Su; Ewa Bryndza-Tfaily; Thomas J Hope; Ronald Veazey; Georgina Dobek; Jiang Qiu; David Watrous; Samuel Sung; Jorge E Chacon; Patrick F Kiser Journal: J Control Release Date: 2020-12-19 Impact factor: 9.776
Authors: Jane M Simoni; Kristin Beima-Sofie; Zahra H Mohamed; Joan Christodoulou; Kenneth Tapia; Susan M Graham; Rodney Ho; Ann C Collier Journal: AIDS Patient Care STDS Date: 2019-03 Impact factor: 5.944
Authors: Tonia Poteat; Benjamin Ackerman; Daouda Diouf; Nuha Ceesay; Tampose Mothopeng; Ky-Zerbo Odette; Seni Kouanda; Henri Gautier Ouedraogo; Anato Simplice; Abo Kouame; Zandile Mnisi; Gift Trapence; L Leigh Ann van der Merwe; Vicente Jumbe; Stefan Baral Journal: PLoS Med Date: 2017-11-07 Impact factor: 11.069